Xtant Medical (US:XTNT)2026-03-31 11:05Revenue Performance - Full year 2025 revenue totaled $134.0 million, an increase of 14% year-over-year from $117.3 million in 2024[2][8] - Fourth quarter 2025 revenue was $32.4 million, up approximately 3% compared to $31.5 million in the prior year quarter[6][8] - Total revenue for the year ended December 31, 2025, was $133.9 million, a 14.3% increase from $117.3 million in 2024[26] Profitability - Net income for the full year 2025 was $5.0 million, or $0.03 per diluted share, compared to a net loss of $16.5 million in 2024[6][11] - Gross margin for the full year 2025 was 62.9%, compared to 58.2% for the full year 2024[6][9] - Gross profit for the year was $84.3 million, up from $68.2 million in 2024, resulting in a gross margin of 63%[26] - Net income for the year was $5.0 million, a significant recovery from a net loss of $16.4 million in 2024[26] - The company reported a non-GAAP EBITDA of $15.8 million for 2025, compared to a loss of $7.9 million in 2024, indicating improved operational efficiency[30] Cash Flow and Financial Position - Operating cash flow for the full year 2025 was $12.5 million, compared to net cash used in operations of $11.9 million in 2024[6][11] - Cash and cash equivalents increased to $17.1 million as of December 31, 2025, compared to $6.2 million at the end of 2024[27] - The company increased its cash position to over $22 million and reduced its term loan balance to $11.2 million[7][14] - Total current assets rose to $78.2 million in 2025 from $67.1 million in 2024, driven by increases in cash and trade accounts receivable[24] - Total liabilities decreased to $43.2 million in 2025 from $50.9 million in 2024, reflecting a reduction in long-term debt[24] - The company’s total stockholders' equity increased to $51.0 million in 2025 from $43.0 million in 2024, indicating a stronger financial position[24] Business Development and Innovation - The company launched new products including the nanOss Strata™ and CollagenX™ in 2025, focusing on innovation in its biologics segment[6][7] - The company completed the sale of non-core assets to Companion Spine for a total of $21.4 million in cash[6][8] - The company anticipates full-year 2026 revenue to be in the range of $95 million to $99 million, reflecting organic growth in its core biologics business[15][21] Operating Expenses - Operating expenses totaled $77.0 million in 2025, down from $80.3 million in 2024, with general and administrative expenses increasing to $29.4 million[26] - Non-GAAP adjusted EBITDA for the full year 2025 was $16.3 million, compared to an adjusted EBITDA loss of $2.3 million for the full year 2024[6][12] Revenue Breakdown - Product revenue decreased to $115.2 million in 2025 from $115.8 million in 2024, while license revenue increased significantly to $18.7 million from $1.5 million[26]